- Home
- JSPR vs DOMO Comparison
JSPR vs DOMO Comparison
Compare JSPR & DOMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JSPR | DOMO |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | United States |
| Employees | 22 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.3M | 171.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | JSPR | DOMO |
|---|---|---|
| Price | $0.91 | $3.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $15.50 | $10.28 |
| AVG Volume (30 Days) | 225.3K | ★ 568.6K |
| Earning Date | 05-12-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.92 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $318,857,000.00 |
| Revenue This Year | N/A | $3.41 |
| Revenue Next Year | N/A | $4.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $0.62 | $2.39 |
| 52 Week High | $7.19 | $18.49 |
Technical Indicators
Market Signals| Indicator | JSPR | DOMO |
|---|---|---|
| Relative Strength Index (RSI) | 50.72 | 52.93 |
| Support Level | $0.81 | $3.32 |
| Resistance Level | $1.03 | $4.11 |
| Average True Range (ATR) | 0.08 | 0.23 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 63.70 | 51.87 |
Price Performance
Historical ComparisonAbout JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
About DOMO Domo Inc. Class B
Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.